Anti-thymocyte globulin (ATG) is immunosuppressive antibody that has been around for >30 years, which is used to prevent graft-versus-host disease (GvHD) and the rejection of transplanted tissue. In this interview, Jaap Jan Boelens, MD, PhD, from UMC Utrecht, Utrecht, Netherlands, speaks about the results of his study investigating the pharmacokinetic profile of ATG in 500 cancer patients that received stem cell transplantation. This video was recorded at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.
Factors determining the effectiveness of treatment with ATG following transplantation
